Caribou Biosciences Stock (NASDAQ:CRBU)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$0.87

52W Range

$0.66 - $4.21

50D Avg

$1.10

200D Avg

$1.75

Market Cap

$74.42M

Avg Vol (3M)

$1.14M

Beta

2.36

Div Yield

-

CRBU Company Profile


Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

147

IPO Date

Jul 23, 2021

Website

CRBU Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24
Reportable Segment$9.99M

Fiscal year ends in Dec 24 | Currency in USD

CRBU Financial Summary


Dec 24Dec 23Dec 22
Revenue-$34.48M$13.85M
Operating Income$-166.62M$-116.06M$-106.40M
Net Income$-149.10M$-102.07M$-99.42M
EBITDA$-166.62M$-112.53M$-104.78M
Basic EPS$-1.65$-1.38$-1.64
Diluted EPS$-1.65$-1.38$-1.64

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison


TickerCompany
ADPTAdaptive Biotechnologies Corporation
EDITEditas Medicine, Inc.
BEAMBeam Therapeutics Inc.
VERVVerve Therapeutics, Inc.
CRSPCRISPR Therapeutics AG
SANASana Biotechnology, Inc.
NTLAIntellia Therapeutics, Inc.
FATEFate Therapeutics, Inc.
PRMEPrime Medicine, Inc.